Editas Medicine
Cell & Gene Therapy · Rare Disease Therapeutics
Has an LEISponsors visas
6Open roles3 posted in 30 days+1 this week
$245kMedian advertised pay$138k – $289k
109EmployeesUS Form 5500 (plan participants) · Dec 2025 · -63% in a year
Facts
as of Nov 13, 2026Editas Medicine is a leading gene editing company focused on developing CRISPR medicines for people with serious diseases.
It is hiring: 6 open roles, 3 of them posted in the last 30 days.
- Founded
- 1986
- Employees
- 109US Form 5500 (plan participants) · Dec 2025 · -63% in a year
- Open roles
- 6Alion job postings
- Official records
- Wikidata Q23131313LEI 5299000AON4Q9NT2JE42SEC CIK 1650664
- Website
- editasmedicine.com
As of Nov 13, 2026, Alion lists 6 open roles at Editas Medicine. It was founded in 1986. The median pay stated in its open roles is $200k, across 6 postings that state pay.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Hiring
All open roles →Hiring at full speed: most open roles are fresh.
Biotech is the largest family, 56 of open roles.
3Posted in 30 days50% of open roles are fresh
0%Remote roles0 of 6
1Hiring offices
Can they hire you from United States?by your location
Likely
9 open roles are in your country: you apply locally, no move needed.
No posting offers visa sponsorship. Remote roles: 0.
Open roles over time+500%
Sep 7This week
Open roles a week: 1 then, 6 now
Where the openings areshare of open roles · trend
Benefits named in postingsshare of open roles
Contract type
Full-Time 4Contract 2
Visa sponsorship: none statedRelocation: none stated
Source: the company's careers site, read by Alion several times a day; market medians from all open roles of the same family
What its postings pay, by level.
$245kMedian
$138k – $289kTypical rangeUSD a year
$372kHighest paying roleVice President, Regulatory Affairs
Pay by levelmiddle half of stated pay, median marked
$0$100k$200k$300k$400k
Source: the pay stated in the company's postings, normalised to USD a year
Visa
Full chapter →Named in the work visa registers of United States.
United StatesUS 2
#4,273 of 8,998 sponsors
2 ▼ 78%H-1B filings in 12 months
2Green card filings
$85kMedian offered salary
Who they sponsor
The salary offered for each occupationVisa pass · 90 credits In the register as EDITAS MEDICINE, INC., Cambridge, MA (+1 more)
Other sponsors in the same field
See 6 open roles Alert me
US Department of Labor · latest filing Jun 11, 2026
Footprint
Hiring in 1 city in 1 country.
1Cities
1Countries
CambridgeBusiest site
Loading the map
| Site | Type | Open roles | Hires most for | Engineering |
|---|---|---|---|---|
| Cambridge United States | Regional office | 6 | Biotech, Communications, Science & Research | 17% |
| Boulder United States | Regional office | 0 |
Source: office addresses in postings and company registers
Tech stack
Full chapter →Technologies named in job postings at Editas Medicine over the last 12 months, by layer, with the share of postings for each.
18Technologies in use
9Postings analysed
75/100Stack modernityAI adopter
Sign in to see how your skills match this stackSign In
Full Editas Medicine tech stack18 technologies · by team · pay by technology · changes · similar stacks
Source: the technologies named in the company's postings and on its site
Milestones
2025
Team shrank to 109 was 294 · US Form 5500 (plan participants)
1986
Founded
Each milestone is dated by its source: registers, filings, the press
Newsroom
top 2%Web presenceof 133.2M domains by links, Common Crawl
Sep 12026
News · markets.businessinsider.com
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developi...
Jun 28, 20252025
News · The Motley Fool
Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?
May 14, 20252025
News · Nasdaq
Explore the exciting world of Editas Medicine (NASDAQ: EDIT) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights…
Dec 13, 20242024
Sep 25, 20242024
News · seekingalpha.com
Jan 15, 20242024
News · The Motley Fool
The past few years have been difficult ones, but shares of the gene editor are far more attractive now that a CRISPR medicine has passed regulatory hurdles.
Sources: the outlets named on each headline, each story once